Mode
Text Size
Log in / Sign up
N/A N=190 Randomized Double-blind Basic Science

Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)

Common Cold

Enrolled (actual)
190
Serious AEs
0.0%
Results posted
Apr 2017
Primary outcome: Primary: Interleukin-8 (IL-8) — 133; 122 pg/ml

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Bifidobacterium lactis Bl-04 (Dietary_supplement); Placebo (Dietary_supplement); Rhinovirus (Biological)
Age
Adult · 18+ yrs
Sex
All
Sponsor
University of Virginia
Primary completion
Jun 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Interleukin-8 (IL-8)
133; 122

Summary

The study is designed to assess the effect of ingestion of a probiotic on innate and adaptive host responses to rhinovirus infection.

Eligibility Criteria

Inclusion Criteria

AT ENROLLMENT:

  • Subject must be 18-60 years of age.
  • Subject must read and sign a copy of the approved Consent Form
  • Female subjects must be using an effective birth control method.

INCLUSION CRITERIA AT DAY -28

  • Subject must read and sign a copy of the approved Consent Form

AT CHALLENGE:

  • Female subjects must be using an effective birth control method.
  • Subject must have a serum neutralizing antibody titer of less than or equal to 1:4 to rhinovirus type 39

Exclusion Criteria

AT ENROLLMENT:

  • Current cancer diagnosis or immunosuppressive therapy in the last 6 months
  • Any clinically significant abnormalities of the upper respiratory tract
  • Any clinically significant acute or chronic respiratory illness
  • Any clinically significant bleeding tendency by history
  • Hypertension that requires treatment with antihypertensive medications
  • History of angina or other clinically significant cardiac disease
  • Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study
  • History of regular use (more than 3 days in 7) of tobacco products within the preceding two weeks
  • History of drug or alcohol abuse in the 6 months preceding the study

EXCLUSION CRITERIA AT DAY -28

  • Antibiotic use within 3 months prior to study start
  • Female subjects with a positive urine pregnancy screen.
  • History of use of probiotics in the preceding 2 weeks.

EXCLUSION CRITERIA AT CHALLENGE:

  • Any upper respiratory infection or allergic rhinitis in the two weeks prior to the start of the study
  • Any medical condition that in the opinion of the Principal Investigator is cause for exclusion from the study
  • Use of any anti-inflammatory (steroids or NSAIDs) or cough/cold preparation in the two weeks prior to the study
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01669603). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search